自首次报告口服哌唑嗪(Prazosin.简写PZ)治疗慢性、严重、血压正常的充血性心衰(CHF),降低了极度增加的心室后负荷的临床效应及其药理特殊性以来,作为血管扩张剂在全身使用,已有大量文献介绍和评论。在改善左心室功能方面,已证实口服哌唑嗪(喹唑酮的衍生物、具有选择性阻滞α_1-肾上腺素能受体的作用)。有硝普钠样、显著降低已升高了的前负荷、减轻呼吸困难、增加心排出量、改善心功能等联合作用,单剂口服PZ其动静脉扩张作用可维持6小时。长期口服PZ的顽固性心衰患者,通过双盲及开放试验的大量报告,其疗效也得到证实。但是,以后报导服PZ后,迅速发生血液动力学作用的亚急性衰减,以致在使用PZ于严重CHF患者发生极大混 Since the first report of oral prazosin (Prazosin. Abbreviation PZ) for the treatment of chronic, severe, normotensive congestive heart failure (CHF) and a greatly reduced clinical effect of ventricular afterload and its pharmacological specificity as vasodilation Agents in the body, there are a lot of literature presentations and comments. In improving left ventricular function, prazosin has been shown to be orally administered (a quinazolinone derivative that selectively blocks alpha 1 -adrenergic receptors). With sodium nitroprusside, significantly reduced the increased preload, reduce dyspnea, increase cardiac output, improve cardiac function and other joint effects, single oral oral PZ its arteriovenous dilation can be maintained for 6 hours. Long-term oral PZ refractory heart failure patients, through a large number of double-blind and open trial reports, the efficacy has also been confirmed. However, subacute decay of hemodynamic effects occurred soon after PZ was reported so that PZ was extremely mixed in patients with severe CHF